Abstract
This Viewpoint aims to provide an understanding of the current contrast in reimbursement for cancer treatment modalities in the US.
Chirag Shah
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Medical care costs associated with cancer survivorship in the United States.
10.1158/1055-9965.epi-19-1534 · 2020
Trends in launch prices and price increases for self-administered anticancer drugs in Medicare.
10.1001/jama.2025.6366 · 2025
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): extended long-term outcomes.
10.1016/j.ijrobp.2022.05.004 · 2022
Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer.
10.1056/nejmoa2202809 · 2022
Implications of Medicare negotiation and most-favored-nation pricing for cancer medicine costs.
10.1001/jamahealthforum.2026.0509 · 2026
An international modified Delphi study to prioritise levels of evidence and outcomes to appraise radiotherapy innovation in the ESTRO Value-Based Radiation Oncology framework.
10.1016/s1470-2045(25)00732-6 · 2026
Unresolved referenced work
Kept as external metadata until matched
No additional external references are available.